Akineton and Ear infection - chronic - from FDA reports


Summary

There is no Ear infection - chronic reported by people who take Akineton yet. This review analyzes which people have Ear infection - chronic with Akineton. It is created by eHealthMe based on reports from FDA, and is updated regularly.

What to expect?

If you take Akineton and have Ear infection - chronic, find out what symptoms you could have in 1 year or longer.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>

On Nov, 18, 2017

No report is found.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

Do you have Ear infection - chronic when taking Akineton?

Expand the study to include all drugs with the same ingredients

Ear infection - chronic and drugs with ingredients of biperiden hydrochloride.

Expand the study to include reports from both FDA and eHealthMe

Ear infection - chronic and Akineton from FDA and eHealthMe reports

Akineton

Akineton has active ingredients of biperiden hydrochloride. It is often used in parkinson's disease. (latest outcomes from Akineton 4,285 users)

Ear Infection - Chronic

Ear infection - chronic has been reported by people with multiple sclerosis relapse (latest reports from 10 Ear infection - chronic patients).

Browse all side effects of Akineton

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Ear infection - chronic

Ear infection - chronic

Could your condition cause Ear infection - chronic

Ear infection - chronic

Related studies

What would happen?

Forecast new side effects and undetected conditions when you take Akineton and have Ear infection - chronic.

Questions to the study

More questions >

User reviews to the study

More reviews >